Table 1 Correlation between circ-ERBB2 expression and clinical characteristics in breast cancer patients
Clinicopathologic parameters | N | circ-ERBB2 expression | p-value | |
|---|---|---|---|---|
Low (%) | High (%) | |||
Age (years) | ||||
 ≤ 40 | 8 | 3 (37.5%) | 5 (62.5%) | 0.750 |
 > 40 | 35 | 18 (51.4%) | 17 (48.6%) | |
Tumor size (cm) | ||||
 ≤ 2 | 30 | 13 (43.3%) | 17 (56.7%) | 0.332 |
 > 2 | 13 | 8 (61.5%) | 5 (38.5%) | |
Lymph node metastasis | ||||
 Negative | 20 | 14 (70.0%) | 6 (30.0%) | 0.010* |
 Positive | 23 | 7 (30.4%) | 16 (69.6%) | |
Histological grade | ||||
 I | 11 | 7 (63.6%) | 4 (36.4%) | 0.214 |
 II | 14 | 8 (57.1%) | 6 (42.9%) | |
 III | 18 | 6 (33.3%) | 12 (66.7%) | |
TNM stage | ||||
 I | 10 | 8 (80.0%) | 2 (20.0%) | 0.090 |
 II | 16 | 8 (50.0%) | 8 (50.0%) | |
 III | 13 | 4 (30.8%) | 9 (69.2%) | |
IV | 4 | 1 (25.0%) | 3 (75.0%) | |
HER2 status | ||||
 Negative | 20 | 15 (75.0%) | 5 (25.0%) | 0.001** |
 Positive | 23 | 6 (26.1%) | 17 (73.9%) | |